Characteristics and treatment results of refractory and relapsed acute myeloid leukaemia in paediatric patients treated in Polish Paediatric Leukaemia/Lymphoma Study Group institutions according to the Protocol Acute Myeloid Leukaemia BerlinFrankfurt-Munster 2012 and a review of novel treatment possibilities in paediatric acute myeloid leukaemia

被引：0

作者：

Samborska, Magdalena ^{[1
,18
]}

Skalska-Sadowska, Jolanta ^{[1
]}

Achkar, Robert ^{[2
]}

Wachowiak, Jacek ^{[1
]}

Derwich, Katarzyna ^{[1
]}

Czogala, Malgorzata ^{[3
]}

Balwierz, Walentyna ^{[3
]}

Skoczen, Szymon ^{[3
]}

Dobaczewski, Grzegorz ^{[4
]}

Chybicka, Alicja ^{[4
]}

Kalwak, Krzysztof ^{[4
]}

Krawczuk-Rybak, Maryna ^{[5
]}

Muszynska-Rostan, Katarzyna ^{[5
]}

Adamkiewicz-Droiynska, Elzbieta ^{[6
]}

Maciejka-Kapuscinska, Lucyna ^{[6
]}

Irga-Jaworska, Ninela ^{[6
]}

Pohorecka, Joanna ^{[7
]}

Chodata-Grzywacz, Agnieszka ^{[7
]}

Karolczyk, Graiyna ^{[7
]}

Wojcik, Beata ^{[7
]}

Kowalczyk, Jerzy R. ^{[8
]}

Drabko, Katarzyna ^{[8
]}

Zawitkowska, Joanna ^{[8
]}

Mycko, Katarzyna ^{[9
]}

Badowska, Wanda ^{[9
]}

Ociepa, Tomasz ^{[10
]}

Urasinski, Tomasz ^{[10
]}

Sikorska-Fic, Barbara ^{[11
]}

Matysiak, Michal ^{[11
]}

Laguna, Pawel ^{[11
]}

Dabrowska-Pawliszyn, Anna ^{[12
]}

Tomaszewska, Renata ^{[12
]}

Szczepanski, Tomasz ^{[12
]}

Sobol, Graiyna ^{[13
]}

Mizia-Malarz, Agnieszka ^{[13
]}

Ciebiera, Malgorzata ^{[14
]}

Chaber, Radoslaw ^{[14
]}

Koltan, Sylwia ^{[15
]}

Wysocki, Mariusz ^{[15
]}

Styczynski, Jan ^{[15
]}

Woszczyk, Mariola ^{[16
]}

Wieczorek, Maria ^{[16
]}

Karpinska-Derda, Irena ^{[16
]}

Urbanska-Rakus, Justyna ^{[16
]}

Bobeff, Katarzyna ^{[17
]}

Trelinska, Joanna ^{[17
]}

Mlynarski, Wojciech ^{[17
]}

机构：

[1] Univ Med Sci, Dept Pediat Hematol Oncol & TransplantolOncol & T, Poznan, Poland

[2] Univ Med Sci, Poznan, Poland

[3] Univ Children Hosp, Dept Pediat Oncol & Hematol, Krakow, Poland

[4] Wroclaw Med Univ, Clin Dept Pediat Bone Marrow Transplantat Oncol &, Wroclaw, Poland

[5] Med Univ, Dept Pediat Oncol & Hematol, Bialystok, Poland

[6] Med Univ, Dept Pediat Hematol & Oncol, Gdansk, Poland

[7] Reg Polyclin Hosp, Dept Pediat Hematol & Oncol, Kielce, Poland

[8] Med Univ, Dept Pediat Hematol Oncol & Transplantol, Lublin, Poland

[9] Prov Childrens Hosp, Dept Pediat & Hematol & Oncol, Olsztyn, Poland

[10] Pomeranian Med Univ, Dept Pediat HematoOncol & Gastroenterol, Szczecin, Poland

[11] Med Univ, Dept Oncol Pediat Hematol Transplantol & Pediat, Warsaw, Poland

[12] Silesian Univ Med, Dept Pediat Hematol & Oncol, Zabrze, Poland

[13] Med Univ Silesia, Katowice, Poland

[14] Clin Prov Hosp, Dept Pediat Oncohematol, Rzeszow, Poland

[15] Nicolaus Copernicus Univ Torun, Dept Pediat Hematol & Oncol, Coll Medicum, Bydgoszcz, Poland

[16] Pediat Ctr, Dept Pediat Hematol & Oncol, Chorzow, Poland

[17] Med Univ, Dept Pediat Oncol & Hematol, Lodz, Poland

[18] Uniwersytet Med Karola Marcinkowskiego, Klin Onkol Hematol & Transplantol Pediat, Poznan, Poland

来源：

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2023年 / 27卷 / 04期

关键词：

children; acute myeloid leukaemia; relapse; refractory; novel therapies; CHILDREN; RECOMMENDATIONS; CHEMOTHERAPY; CYTARABINE; MANAGEMENT; DIAGNOSIS;

D O I：

10.5114/wo.2023.135327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: This study aimed to present the clinical features and results of treatment of patients diagnosed with refractory or relapsed acute myeloid leukaemia (AML) in Polish Paediatric Leukaemia/Lymphoma Study Group (PPL/LSG) institutions, treated in accordance with the Protocol Acute Myeloid Leukaemia Berlin -Frankfurt -Munster 2012, as their first -line therapy. Material and methods: The outcome data of 10 patients with refractory AML (median age 9.5 years) and 30 with relapsed AML (median age 12 years) were analysed retrospectively. Re -induction was usually based on idarubicin, fludarabine, and cytarabine along with allogeneic haematopoietic stem cell transplant (allo-HSCT) in 5 patients with refractory AML and 7 relapsed AML children. Results: 37.5% (3/8) of refractory AML patients achieved second complete remission second complete remission (CRII). One of ten patients (1/10; 10%) was alive and stayed in complete remission for 34 months after the allo-HSCT. The probability of 3 -year event -free survival (pEFS) in this group was 0.125 +/- 0.11. In the group of relapsed AML patients, the CRII was achieved in 9 patients (34%), and the probability of survival was: pEFS = 0.24 +/- 0.08; probability overall survival (pOS) = 0.34 +/- 0.09, with significantly better results achieved in patients who underwent allo-HSCT (pOS = 0.54 +/- 0.14 vs. 0.08 +/- 0.08, p < 0.0001). Conclusions: The prognosis of refractory AML and the first AML recurrence in children who were first -line treated in PPL/LSG centres according to Protocol Acute Myeloid Leukaemia Berlin -Frankfurt -Munster 2012 is poor. Failures of re -induction treatment particularly result from difficulties in achieving remission. Allogeneic HSCT improves prognosis in children with refractory and first recurrent AML, under the condition it is performed in complete remission. Novel therapeutic approaches are needed to increase the remission rate and improve the outcomes.

引用

页码：249 / 254

页数：6

共 50 条

[31] Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia
Tse, Eric
Leung, Anskar Y. H.
Sim, Joycelyn
Lee, Harold K. K.
Liu, Herman S. Y.
Yip, Sze-Fai
Kwong, Yok-Lam
ANNALS OF HEMATOLOGY, 2011, 90 (11) : 1277 - 1281
[32] Exploring Compounds Which have the Potential to be Repurposed into Induction Therapy for Paediatric Patients with Acute Myeloid Leukaemia
Lappin, K.
Matchett, K.
Mills, K.
PEDIATRIC BLOOD & CANCER, 2018, 65 : S181 - S182
[33] A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia
Esperanza-Cebollada, Elena
Gomez-Gonzalez, Soledad
Perez-Jaume, Sara
Vega-Garcia, Nerea
Vicente-Garces, Clara
Richarte-Franques, Merce
Rives, Susana
Catala, Albert
Torrebadell, Montserrat
Camos, Mireia
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (01) : 96 - 110
[34] Role of acute GVHD in paediatric patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia: an imperfect balance
Lucchini, G.
Bertaina, A.
Galimard, J. E.
Benakli, M.
Kalwak, K.
Dalle, J. H.
Danicar, O. Mirci
Ayas, M.
Locatelli, F.
Skorobogatova, E.
Bertrand, Y.
Styczynski, J.
Tbakhi, A.
Sedlacek, P.
Balduzzi, A.
Ifversen, M.
Versluijs, B.
Jubert, C.
Dalissier, A.
Bader, P.
Corbacioglu, S.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 88 - 88
[35] Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol
Muhamad, Nor A.
Mohd Dali, Nor S.
Yacob, Aliza Mohd
Kassim, Mohd S. A.
Lodz, Noor A.
Abdul Wahid, S. F.
Aris, Tahir
BMJ OPEN, 2020, 10 (06):
[36] Impact of Acute Lymphoblastic Leukaemia Treatment on the Nutritional Status of Paediatric Patients: A Systematic Review
Picans-Leis, Rosaura
Nieto, Fatima
Romero-Agrelo, Anabel
Izquierdo-Lopez, Isabel
Rivas-Rodriguez, Lucia
Vazquez-Cobela, Rocio
Leis, Rosaura
NUTRIENTS, 2024, 16 (23)
[37] The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)
Betts, David R.
Ammann, Roland A.
Hirt, Andreas
Hengartner, Heinz
Beck-Popovic, Maja
Kuhne, Thomas
Nobile, Luisa
Caflisch, Ueli
Wacker, Pierre
Niggli, Felix K.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 (06) : 468 - 476
[38] Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients
LeBlanc, Francis R.
Breese, Erin H.
Burns, Karen C.
Chang, Ellen K.
Jones, LaQuita M.
Lee, Lynn
Mizukawa, Benjamin
Norris, Robin E.
O'Brien, Maureen M.
Phillips, Christine L.
Perentesis, John P.
Rubinstein, Jeremy
Pommert, Lauren
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 1055 - 1066
[39] Treatment rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India - response to Gupta etal
Philip, Chepsy
George, Biju
Korula, Anu
Srivastava, Alok
Balasubramanian, Poonkuzhali
Mathews, Vikram
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (02) : 347 - 349
[40] Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia
Smith, Amanda M.
Little, Erica B.
Zivanovic, Andjelija
Hong, Priscilla
Liu, Alfred K. S.
Burow, Rachel
Stinson, Caedyn
Hallahan, Andrew R.
Moore, Andrew S.
LEUKEMIA RESEARCH, 2015, 39 (04) : 435 - 444

← 1 2 3 4 5 →